Osr Health, Inc. (OSRH) Stock Price & Analysis
Osr Health, Inc. (OSRH) fell 6.04% to USD 0.42 as of July 25, 2026 at 08:27 UTC, according to Nexqual real-time market data.
OSRH last closed at USD 0.45; the session ranged USD 0.42–0.46 on volume of 266,893 shares. Market capitalization is $14.84M, with a 52-week range of USD 0.3–1.24 (NCM). Source: Nexqual, July 25, 2026 at 08:27 UTC.
Key Statistics (as of July 25, 2026 at 08:27 UTC)
| Price | USD 0.42 |
|---|---|
| Change | ▼ 6.04% (down) |
| Previous Close | USD 0.45 |
| Open | USD 0.44 |
| Day Range | USD 0.42 – 0.46 |
| 52-Week Range | USD 0.3 – 1.24 |
| Volume | 266,893 shares |
| Market Cap | $14.84M |
| Exchange | NCM |
Technical Analysis (OSRH)
Nexqual's technical model rates OSRH "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 08:27 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.15 (neutral) |
| vs SMA50 | Above (USD 0.41) |
| MACD | 0.01 (positive) |
Analyst Ratings (OSRH)
Wall Street analysts rate OSRH "None" based on 1 analysts, with a mean price target of USD 10 (range USD 10–10), per Nexqual as of July 25, 2026 at 08:27 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 10 |
| High Target | USD 10 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (OSRH)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.16 vs est -0.1 ▼ miss |
Source: Nexqual, July 25, 2026 at 08:27 UTC.
Financials & Fundamentals (OSRH)
| Total Revenue | $2.63M |
|---|---|
| Revenue Growth (YoY) | -36.40% |
| Gross Margin | +20.85% |
| Operating Margin | -757.59% |
| Profit Margin | +0.00% |
| ROE | -14.74% |
| Debt / Equity | 3.89 |
| Current Ratio | 0.16 |
| Total Cash | $1.57M |
| Total Debt | $4.95M |
| Free Cash Flow | $1.38M |
Source: Nexqual, July 25, 2026 at 08:27 UTC.
Financial Health Score (OSRH)
Nexqual rates Osr Health, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 08:27 UTC.
| Growth | Critical — Revenue -36% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Solid — $2M cash vs $5M debt |
| Cash Flow | Strong — FCF $1M, 48% margin |
| Efficiency | Critical — ROE -15%, ROA -6.9% |
Ownership (OSRH)
| Insider Ownership | +48.97% |
|---|---|
| Institutional Ownership | +0.83% |
| Shares Outstanding | 35.10M |
| Float | 14.65M |
| Short % of Float | +12.62% |
Source: Nexqual, July 25, 2026 at 08:27 UTC.
Leadership (OSRH)
Osr Health, Inc. is led by Kuk Hyoun Hwang (age 49), Chairman & CEO, per Nexqual as of July 25, 2026 at 08:27 UTC.
| Chairman & CEO | Kuk Hyoun Hwang (age 49) |
|---|---|
| Chief Financial Officer | Gihyoun Bang (age 47) |
| Chief Scientific Officer | Constance Hofer (age 56) |
| Chief Legal Officer, Secretary & Director | Jun Chul Whang (age 60) |
| Chief Operating Officer | Yeiseok Kim (age 35) |
Major Backers & Investors (OSRH)
Notable institutional backers of Osr Health, Inc. include Fidelity, Xtx Topco Ltd, Toronto Dominion Bank, according to Nexqual as of July 25, 2026 at 08:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 0.24% |
| Xtx Topco Ltd | 0.17% |
| Toronto Dominion Bank | 0.11% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 0.3% |
| Vanguard Group | 0.27% |
Source: Nexqual, July 25, 2026 at 08:27 UTC.
From Osr Health, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- VXM01 and the underlying proprietary platform, further, has the potential to target multiple indications, even beyond oncology.   VXM01 has recently completed a Phase 2 clinical trial in Europe for the treatment of recurrent glioblastoma, where activity has been observed to date.
Partnerships
- We collaborate with academic and industry leaders to promote a seamless integration and partnership between entrepreneurial scientists and seasoned business development and leadership teams.
- RMC's distribution agreement with Penumbra Inc. for the resale of its reperfusion catheter, neuron delivery catheter and related tubing and canister, expired on June 30, 2024.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| XHLD | TEN Holdings, Inc. | USD 1.86 | ▼ 11% |
| KIDZ | KIDZ AI Inc. | USD 0.42 | ▼ 26.86% |
| CYCU | Cycurion, Inc. | USD 0.32 | ▲ 3.23% |
| ASBP | Aspire Biopharma Holdings, Inc. | USD 7.26 | ▼ 6.44% |
| NIVF | NewGenIvf Group Limited | USD 1.1 | ▼ 13.39% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 08:27 UTC. This page is informational and not investment advice.